Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ:SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced strong growth in Asia Pacific, primarily fueled by growth in its Advanced Messaging business
Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the
